Cardiodiabesity: Epidemiology, Resource and Economic Impact

Overview

Journal Am J Prev Cardiol

Specialty Cardiology & Vascular Diseases

Date 2024 Nov 25

PMID 39583639

Authors

Duy Do

Tiffany Lee

Calie Santana

Angela Inneh

Urvashi Patel

Affiliations

Soon will be listed here.

Abstract

Objective: To assess i) the epidemiology of cardiodiabesity, ii) its association with healthcare resource utilization and cost of care, as well as iii) provide recommendations for its management.

Methods: A cohort study of insured adults with early-stage and/or active cardiodiabesity from January 2019 to December 2021 identified through a longitudinal, and de-identified medical and pharmacy claims database was conducted. All patients were followed for one year through December 2022. Conditions include cardiovascular disease, prediabetes, Type 2 diabetes (T2D), chronic kidney disease (CKD), overweight and/or obesity. Rates of progression from early-stage cardiodiabesity to active cardiodiabesity and/or advanced cardiodiabesity with complications; frequency of emergency department, inpatient and outpatient visits; as well as total cost of care over one year were analyzed.

Results: A total of 3,273,813 and 1,628,407 patients had at least one of the comorbid conditions for early-stage and active cardiodiabesity, respectively. Among those with all early-stage cardiodiabesity conditions, 27.4 % progressed to active cardiodiabesity, while 88.4 % of those with all active cardiodiabesity conditions progressed to complications within one year. Predictors of progression from early-stage to active cardiodiabesity were hypertension (OR: 2.31, 95 % CI: 2.29-2.33, < 0.001), hyperlipidemia (OR: 1.77, 95 % CI: 1.76-1.79, < 0.001), CKD stages 1 and 2 (OR: 1.74, 95 % CI: 1.69-1.79, < 0.001), prediabetes (OR: 1.64, 95 % CI: 1.63-1.66, < 0.001) and living in areas with very high social needs (OR: 1.25, 95 % CI: 1.23-1.26, < 0.001). Significant predictors of progression from active cardiodiabesity to complications were T2D (OR: 1.88, 95 % CI: 1.81-1.96, < 0.001), CVD (OR: 1.47, 95 % CI: 1.44-1.51, < 0.001), CKD stages 3 and 4 (OR: 1.37, 95 % CI: 1.34-1.41, < 0.001) and obesity (OR: 1.29, 95 % CI: 1.26-1.32, < 0.001). Average total cost of care increased significantly among those who progressed from one disease phase to the next (p < 0.05).

Conclusions: Cardiodiabesity is deadly and rapidly progressive with substantial economic burden on the healthcare system. However, it is preventable. Innovative approaches to better understand the holistic impact of cardiodiabesity on total cost of care, early intervention or management to halt disease progression and promote equity, as well as decrease resource utilization are needed.

References

Roche M, Wang P . Factors associated with a diabetes diagnosis and late diabetes diagnosis for males and females. J Clin Transl Endocrinol. 2017; 1(3):77-84. PMC: 5685052. DOI: 10.1016/j.jcte.2014.07.002. View

Hirode G, Wong R . Trends in the Prevalence of Metabolic Syndrome in the United States, 2011-2016. JAMA. 2020; 323(24):2526-2528. PMC: 7312413. DOI: 10.1001/jama.2020.4501. View

King A, Rajpura J, Liang Y, Paprocki Y, Uzoigwe C . Impact of cardiovascular disease on health care economic burden and resource utilization: a retrospective cohort study in adults in the United States with type 2 diabetes with or without stroke, myocardial infarction, and peripheral arterial disease. Curr Med Res Opin. 2022; 38(11):1831-1840. DOI: 10.1080/03007995.2022.2125259. View

SIMS E, DANFORTH Jr E, Horton E, Bray G, Glennon J, Salans L . Endocrine and metabolic effects of experimental obesity in man. Recent Prog Horm Res. 1973; 29:457-96. DOI: 10.1016/b978-0-12-571129-6.50016-6. View

Ryden L, Standl E, Bartnik M, Van den Berghe G, Betteridge J, de Boer M . Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J. 2007; 28(1):88-136. DOI: 10.1093/eurheartj/ehl260. View

OHearn M, Lauren B, Wong J, Kim D, Mozaffarian D . Trends and Disparities in Cardiometabolic Health Among U.S. Adults, 1999-2018. J Am Coll Cardiol. 2022; 80(2):138-151. PMC: 10475326. DOI: 10.1016/j.jacc.2022.04.046. View

OConnor P, Desai J, RUSH W, Cherney L, Solberg L, Bishop D . Is having a regular provider of diabetes care related to intensity of care and glycemic control?. J Fam Pract. 1998; 47(4):290-7. View

Cowie C . Diabetes Diagnosis and Control: Missed Opportunities to Improve Health : The 2018 Kelly West Award Lecture. Diabetes Care. 2019; 42(6):994-1004. PMC: 6609950. DOI: 10.2337/dci18-0047. View

Kamble P, Hayden J, Collins J, Harvey R, Suehs B, Renda A . Association of obesity with healthcare resource utilization and costs in a commercial population. Curr Med Res Opin. 2018; 34(7):1335-1343. DOI: 10.1080/03007995.2018.1464435. View

10.

Lewing B, Sansgiry S, Abughosh S, Lal L, Essien E, Sansgiry S . Effect of inadequate care on diabetes complications and healthcare resource utilization during management of type 2 diabetes in the United States. Postgrad Med. 2022; 134(5):494-506. DOI: 10.1080/00325481.2022.2061260. View

11.

Rowley W, Bezold C, Arikan Y, Byrne E, Krohe S . Diabetes 2030: Insights from Yesterday, Today, and Future Trends. Popul Health Manag. 2016; 20(1):6-12. PMC: 5278808. DOI: 10.1089/pop.2015.0181. View

12.

Mohebi R, Chen C, Ibrahim N, McCarthy C, Gaggin H, Singer D . Cardiovascular Disease Projections in the United States Based on the 2020 Census Estimates. J Am Coll Cardiol. 2022; 80(6):565-578. PMC: 9396356. DOI: 10.1016/j.jacc.2022.05.033. View

13.

Liang X, Or B, Tsoi M, Cheung C, Cheung B . Prevalence of metabolic syndrome in the United States National Health and Nutrition Examination Survey 2011-18. Postgrad Med J. 2023; 99(1175):985-992. DOI: 10.1093/postmj/qgad008. View

14.

Chen R, Safiri S, Behzadifar M, Kong J, Zguira M, Bragazzi N . Health Effects of Metabolic Risks in the United States From 1990 to 2019. Front Public Health. 2022; 10:751126. PMC: 8841675. DOI: 10.3389/fpubh.2022.751126. View

15.

Jardim T, Mozaffarian D, Abrahams-Gessel S, Sy S, Lee Y, Liu J . Cardiometabolic disease costs associated with suboptimal diet in the United States: A cost analysis based on a microsimulation model. PLoS Med. 2019; 16(12):e1002981. PMC: 6917211. DOI: 10.1371/journal.pmed.1002981. View

16.

Garcia-Fernandez E, Rico-Cabanas L, Rosgaard N, Estruch R, Bach-Faig A . Mediterranean diet and cardiodiabesity: a review. Nutrients. 2014; 6(9):3474-500. PMC: 4179172. DOI: 10.3390/nu6093474. View

17.

Weng W, Tian Y, Kong S, Ganguly R, Hersloev M, Brett J . Impact of atherosclerotic cardiovascular disease on healthcare resource utilization and costs in patients with type 2 diabetes mellitus in a real-world setting. Clin Diabetes Endocrinol. 2020; 6:5. PMC: 7057457. DOI: 10.1186/s40842-019-0090-y. View

18.

Ward Z, Bleich S, Cradock A, Barrett J, Giles C, Flax C . Projected U.S. State-Level Prevalence of Adult Obesity and Severe Obesity. N Engl J Med. 2019; 381(25):2440-2450. DOI: 10.1056/NEJMsa1909301. View